ViaCyte hauls in $5.4M for diabetes drug; Eisai's cancer drug flunks a Phase III;

@FierceBiotech: EuroBiotech report: Roche commits to Danish RNA lab, £3B London incubator hits go, Biotechs in post-IPO slump. Report | Follow @FierceBiotech

@JohnCFierce: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Story | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> ViaCyte raised $5.4 million in Series C cash to support its work on VC-01, a cell therapy treatment for diabetes. News

> Eisai's eribulin failed to meet its primary endpoint of overall survival in a Phase III trial on patients with non-small cell lung cancer. Story (PDF)

> Nicox has exercised its right co-market latanoprostene bunod, a Bausch + Lomb-partnered treatment for glaucoma and ocular hypertension. More

Medical Device News

@FierceMedDev: Physicians hesitate to use HeartMate II pump after NEJM study, Thoratec down 30%. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Scientist robot gets venture funding from Omega. Item | Follow @StacyALawrence

@VarunSaxena2: Elizabeth Pritts says her study's estimate of uterine sarcoma in morcellator patients will be 1:7450 morcellation. More | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. More | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific subpoenaed by federal investigators over cardiology devices start-up. MassDevice story | Follow @EmilyWFierce

> Medtronic and Covidien face FTC pushback for pending merger. News

> GE-funded NGO aims to repair developed-world medical devices in the developing world. More

> Four unanswered questions about the looming LDT regulations. Item

Pharma News

@FiercePharma: Top in FierceVaccines Thursday: Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article | Follow @FiercePharma

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. Green Bay Press Gazette story | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Like it? Subscribe here free. | Follow @CarlyHFierce

> Pfizer faces growing legal threat over Lipitor. News

> NICE raises ire of breast cancer patients with rejection of Roche's Kadcyla. Article

> Novartis can't convince judge to free it from kickbacks case. More